LifeWatch AG

EANS-Adhoc: LifeWatch AG: Results for the second quarter 2012 confirm turnaround (with document)

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
3-month report/LifeWatch AG

22.08.2012

+ EBIT of USD 0.04 million and EBITDA of USD 1.04 million;

+ Reduction of total direct and departmental expenses of USD 5.4 million;

+ 30% Headcount reduction;

+ Improved gross margin of 55.1%;

+ Additional 17 new contracts for ACT and HST respectively;


International analyst and media conference and audio web cast on LifeWatch Q2
2012 financial results

- Wednesday, August 22, 2012 at 10.00 a.m. CEST;
- Dial-in number: + 41 (0)91 610 56 00 (Europe), + 44 (0)203 059 58 62 (UK), +1
(1)866 291 41 66 (USA - Toll-free)
- Audio web cast http://services.choruscall.eu/links/lifewatch120822.html


Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading provider of wireless telemedicine, today announces the results for
the second quarter 2012. The Company continues to improve operating profit on
EBIT and EBITDA level and its gross margin. Total department expenses were
reduced to 54.9% of revenues. Furthermore LifeWatch succeeded in closing 17
additional contracts for its ACT services and Home Sleep Testing, respectively.

You will find a PDF-version of this press release and of the letter to
shareholders with the results of Q2 2012 at the end of this message.


Second Quarter 2012 Financial Highlights:


    - Revenues of USD 19.06 million, compared with USD 20.15 million in Q2 2011.

    - Gross margin was 55.1% compared with 43.8% in Q2 2011.



    - Total departmental expenses were 54.9% of revenues compared with 86.2% in
Q2 2011:


      - R&D expenses decreased by approximately USD 0.52 million


      - S&M expenses decreased by USD 1.63 million compared with Q2 2011



      - G&A expenses decreased by USD 0.49 million from Q2 2011


    - EBIT of USD 0.04 million compared with LBIT of USD 8.55 million in Q2
      2011.



    - EBITDA of USD 1.04 million compared with LBITDA of USD 7.02 million in Q2
2011.



Managed Care Updates:

LifeWatch continues to prove to providers the value of our cost effective
health monitoring services.


    - 17 new contracts for ACT Services


    - 17 new contracts for NiteWatch services.

These new agreements represent over 6 million covered lives and further
validate the awareness of payors to provide coverage for innovative and cost-
effective technologies that offer the potential for better clinical outcomes.


Monitoring Services Updates:

In March 2012 LifeWatch announced a joint development with U.S. medical
technology developer Ansar on a innovative Parasympathetic & Sympathetic (P&S
Monitoring) platform that can be used together with the ACT III wireless
cardiac monitoring system. A total of 8 clinical sites are currently evaluating
the Ansar with ACT monitoring platform, and a further 20 clinics are very
interested in assessing this technology. The Company is engaged in embedding the
Ansar platform on an innovative wearable sensor for improved user-friendliness.

The Elite software-defined technology and cardiac monitoring service, which was
launched in Q1 2012, has been widely embraced by physicians who value the
streamlined enrolment and billing processes. The remotely programmable feature,
which allows the platform to operate as an ACT telemetry system, a 24-48 hour
Holter, or a cardiac event monitor with auto-detect/auto-send functionality,
eliminates the need for a patient to travel back and forth to a physician in
order to be fitted with an additional monitor, thus shortening the time to a
potential diagnosis.


Technology Update:

LifeWatch unveiled the LifeWatch V, the first-of-its-kind healthcare
smartphone, at two launch events in June and July of 2012. The health and
wellness platform generated strong interest from pharma companies, cellular
service providers, distributors and consumers around the world. With the
services embedded on LifeWatch V platform LifeWatch plan to target this
solution to both consumers and to those with chronic diseases in new
geographies. The LifeWatch V operates on an android operating system that
embeds a multitude of miniature medical sensors and wellness-related
applications on the smartphone which communicates through a cloud-based
ecosystem. By using the barely visible sensors on the phone's frame, patients
as well as health- conscious consumers can track, capture, collect and analyze
their health and medical measurements anywhere anytime. The sensors include a
1-lead ECG, body temperature, blood glucose, heart rate, blood oxygen
saturation, body fat percentage and stress levels as well as drug titration and
a special diet software program. The LifeWatch V wirelessly interacts with a
cloud-based environment allowing users direct access to a wide range of valuable
complementary medical and wellness related services. The Company is expecting
partial regulatory approvals by the end of 2012 and is in discussions with a
number of multi-national companies.


Q2 2012 Revenues:

Revenues this quarter reached USD 19.06 million, a decrease of 5.4% over Q2
2011. On August 1st, the company hired a seasoned professional, Mark Bogart, as
Executive Vice President of Sales at LifeWatch Services, Inc., our US-based
monitoring services business. Mr. Bogart brings considerable knowledge and
business experience in our industry, having led sales organizations in two
similar cardiac monitoring companies over the past 15 years.


Gross Profit, EBITDA and LBIT: 


    - Gross profit was USD 10.49 million in Q2 2012, showing an improved margin
of 55.1%, compared with gross profit of USD 8.82 million, with  a margin of
43.8% in Q2 2011.


    - EBITDA was USD 1.04 million in Q2 2012, compared to LBITDA of USD 7.02
      million in Q2 2011.


    - EBIT dramatically improved to reach USD 0.04 million this quarter,
      compared with LBIT of USD 8.55 million in Q2 2011.

The improved results are mainly a result of the decrease in headcount and
otheroperating expenses.


Net Loss: 


LifeWatch reported a net loss of USD 1.38 million compared to a net loss of USD
10.07 million in Q2 2011. Our net loss was mainly affected by ,non cash,
deferred income tax expenses related to LifeWatch Services Inc. Loss per share
was USD 0.11 (fully diluted), compared to a loss per share of USD 0.81 (fully
diluted) reported in the second quarter of 2011.


Outlook 2012:

LifeWatch has made considerable progress in improving its profitability in
2012. The very challenging reimbursement environment of the U.S. healthcare
system and the unforeseeable impact of the presidential elections in autumn
2012 do not allow any reliable and precise forecast for full fiscal year 2012.
Although the Company will cope with these strong conditions, we are actively
evaluating our new service and technology offerings and strategic partnerships
in order to create more service and geographical diversification. Thus the
Company will improve its revenue streams and lower its reliance on reimbursed-
based business.

Yacov Geva, Chariman and CEO says: "We feel that with our a proven track record
in technological innovations and remote medical monitoring and services we are
well positioned to meet the challenges of a fast moving industry and to target
new business opportunities and geographies. We believe that we have a unique
experience in combining technological innovations with providing specific
medical related services. While we also have a lot of experience in regulated
markets, our new LifeWatch V health and life style offering targets non
regulated markets such as consumer health and new geographies with high revenue
potential."


About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch AG has operative subsidiaries in the United
States, in Switzerland and in Israel and is the parent company of LifeWatch
Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a
leading US-based provider of cardiac monitoring services and home sleep testing
of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel,
is a leading developer and manufacturer of telemedicine products. The Company is
planning to introduce the LifeWatch V, an Android-based smartphone with medical
sensors and apps that uses a cloud-based service platform. For additional
information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are forward-
looking statements. The words "believe," "may," "will," "estimate,"
"continue,""anticipate," "intend"e"expect" and similar expressions are intended
to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT
CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES
FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD
OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION
UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
UNITED STATES SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN
THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED
FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/8OrWIbpx
http://resources.euroadhoc.com/us/9qJNp19Q

Further inquiry note:
Sensus Investor and Public Relations, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/8OrWIbpx
http://resources.euroadhoc.com/us/9qJNp19Q


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:     users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
             SIX Swiss Exchange 
language:   English
 

Original-Content von: LifeWatch AG, übermittelt durch news aktuell

Weitere Meldungen: LifeWatch AG

Das könnte Sie auch interessieren: